<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452592</url>
  </required_header>
  <id_info>
    <org_study_id>20180208</org_study_id>
    <nct_id>NCT03452592</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M</brief_title>
  <official_title>Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allist Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allist Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced&#xD;
      or metastatic non-small cell lung cancer patients harbouring T790M mutation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized and open Ⅱb phase study assessing the efficacy and safety&#xD;
      of Alflutinib at doses of 80 mg orally /once daily and 160 mg orally /once daily in patients&#xD;
      with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) harboring acquired&#xD;
      T790M mutation after EGFR-TKI treatment or primary T790M mutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Evaluation of the objective response rate of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring acquired T790M mutation by prior therapy with an EGFR-TKI or primary T790M mutation assessed by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free disease of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Evaluation of the overall survival of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring acquired T790M mutation by prior therapy with an EGFR-TKI or primary T790M mutation assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Evaluation of the duration of response of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring acquired T790M mutation by prior therapy with an EGFR-TKI or primary T790M mutation assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Progression of tumor was assessed by RECIST 1.1 thereby to evaluate disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Clinical benefit rate was calculated by adding up complete remission, partial remission and stabilization of disease assessed by RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Advanced NSCLC Patients With T790M</condition>
  <arm_group>
    <arm_group_label>The way patients take Alflutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients take Alflutinib orally once per day at dose of 80mg or160mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alflutinib</intervention_name>
    <description>Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg</description>
    <arm_group_label>The way patients take Alflutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Male or female, aged at least 18 years.&#xD;
&#xD;
          -  2.Histologically or cytologically confirmed, and locally advanced or metastatic NSCLC,&#xD;
             who are not suitable for surgery /radiotherapy.&#xD;
&#xD;
          -  3.Patients who have disease progression after continuous previous treatment of&#xD;
             1st/2nd-generation EGFR TKIs (evaluation according to imaging evidence, judged by&#xD;
             research center) will be recruited and primary T790M mutation patients are allowed to&#xD;
             have received no EGFR-targeting therapy before detection.&#xD;
&#xD;
          -  4.The tissue/cell specimen collected from patients who have received the recent&#xD;
             treatment (either TKI or chemotherapy) progression should be confirmed to T790M&#xD;
             positive mutation by the detection of central laboratory, while no specimen collection&#xD;
             requirements for the primary T790M mutation patients.&#xD;
&#xD;
          -  5. ECOG performance status of 0 to 2. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  6. At least one measurable lesion by CT or MRI. The measureable lesion should receive&#xD;
             no local treatments, such as, radiotherapy. If the lesions located at the regions&#xD;
             which were previously treated are confirmed to progress, they can be chosen as lesion&#xD;
             according to RECIST Version 1.1.&#xD;
&#xD;
          -  7. Organ function must meet the following requirements (patients should receive no&#xD;
             blood transfusion, blood product, hematopoietic stimulating factors, and albumin)：&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1.5 x 109/L, Platelet count &gt;= 75 x109/L,&#xD;
                  Haemoglobin &gt;= 90 g/L;&#xD;
&#xD;
               -  Alanine aminotransferase/Aspartate aminotransferase &lt;= 2.5 times the upper limit&#xD;
                  of normal (ULN) if no demonstrable liver metastases or &lt;= 5 times in the presence&#xD;
                  of liver metastases;&#xD;
&#xD;
               -  Total bilirubin &lt;= 1.5 times ULN if no liver metastases or &lt;= 3 times ULN in the&#xD;
                  presence of liver metastases;&#xD;
&#xD;
               -  Creatinine &lt;=1.5 times ULN concurrent with creatinine clearance &gt;= 50 ml/min&#xD;
                  (measured or calculated by Cockcroft and Gault equation);&#xD;
&#xD;
          -  8. Females who have fertility potential before menopause should have a pregnancy test&#xD;
             in the time period of 7 days prior to start of dosing, should not be breast feeding&#xD;
             and must have a negative pregnancy test (blood test or urinalysis) prior to start of&#xD;
             dosing; all enrolled patients should take the barrier contraceptive methods during the&#xD;
             therapy and three months after therapy&#xD;
&#xD;
          -  9. Patients are volunteered to enroll and sign a written informed consent form, and&#xD;
             they can follow the therapeutic schedule and visit plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Previous treatment as follows: Patients received any cytotoxic chemotherapy or&#xD;
             immunotherapy (such as, PD-1 antibody, PD-L1antibody) from a previous treatment&#xD;
             regimen or clinical study within 21 days prior to study entry; The time from stopping&#xD;
             taking any target cancer drug of a previous treatment to study entry is less than its&#xD;
             5x half-life (such as, the time for erlotinib is less than 8 days, the time for&#xD;
             gefinitib is less than 10 days, the time for icotinib is less than 2 days, the time&#xD;
             for afatinib is less than 8 days ); The time from stopping taking any studied drug or&#xD;
             anti-cancer drug of a previous treatment to study entry is less than its 5x half-life;&#xD;
             Patients performed on major surgery within 4 weeks prior to study entry (excluding&#xD;
             from and vascular passage-rebuilt surgery and biopsy operation); Patients performed on&#xD;
             more than 30% of bone marrow radiotherapy or large area irradiation&#xD;
&#xD;
          -  2. Patients previously treated by 3nd-generation EGFR-TKI , analogous drug (such as&#xD;
             Osimertinib (Tagrisso®, AZD9291), Rociletinib (CO-1686), Olmutinib (Olita®,HM61713),&#xD;
             ASP8273, EGF816, HS-1029, and avitinib), or their bulk drugs and generic drug。&#xD;
&#xD;
          -  3. Patients were taking and could not stop the drugs within 2 weeks prior to study&#xD;
             entry. The drugs are as following:&#xD;
&#xD;
               -  Potent inhibitors or inducers of CYP3A4;&#xD;
&#xD;
               -  Traditional Chinese medicine and preparations whose therapeutic goal is&#xD;
                  anti-tumors；Antitumor adjuvant therapy of Traditional Chinese medicine and&#xD;
                  preparations; Drugs with antitumor activity for patients judged by investigator.&#xD;
&#xD;
          -  4. Unrecovered toxic reaction due to former therapy existed, with over 1 grade of&#xD;
             CTCAE (except alopecia) or 2 grade if ever applied DDP curing related neuropathy.&#xD;
&#xD;
          -  5. Spinal compression, or brain metastasis exhibiting symptoms but untreated (except&#xD;
             those exhibit no symptom with stable condition and do not apply corticosteroids for 4&#xD;
             weeks before the trail initiating)&#xD;
&#xD;
          -  6. Any evidence showing severe or inadequate controlled systemic disease. For example&#xD;
             patients with inadequate controlled hypertension considered not suitable for the trail&#xD;
             or would affect the compliance towards the protocol, with active hemorrhagic tendency,&#xD;
             with active infection such as HBV (HBV-DNA≥1000cps/ml), with HCV, with HIV et al&#xD;
             (except for HBV carrier those the researcher considered meet the criterion).&#xD;
&#xD;
          -  7. Any condition affecting the drug taking, or significantly affecting the absorption&#xD;
             or the pharmacokinetic parameters, include any kind of uncontrollable nausea or vomit,&#xD;
             chronic gastroenteropathy, disability in swallowing, and history of gastrointestinal&#xD;
             resection or surgery.&#xD;
&#xD;
          -  8. Any condition meet the following cardiac standard: ECG show a QTc&gt;470 msec under&#xD;
             resting state (Repeat in 48 hours when a first abnormal discovered, take mean of the&#xD;
             two measurements). All kinds of abnormal in cardiac rhythm, conduction and resting ECG&#xD;
             profile with clinical significance, for example complete left bundle branch block, 2&#xD;
             or 3 grade of conduction block and a PR interval&gt;250 msec. Any possible factors&#xD;
             increasing the risk of QTc extending or leading to arrhythmia, such as heart failure,&#xD;
             hypokalemia, congenital long QT syndrome, any first degree relative suffered from long&#xD;
             QT syndrome or undertook unexplained sudden death before 40 years old, or taking any&#xD;
             drug leading to a longer QTc.&#xD;
&#xD;
          -  9. Echocardiographic examination: LVEF&lt;50%&#xD;
&#xD;
          -  10. Any history of interstitial lung disease, drug induced interstitial lung disease,&#xD;
             radiation pneumonia require steroid therapy or active interstitial lung disease with&#xD;
             clinical evidence during recruiting.&#xD;
&#xD;
          -  11. Lung functional examination: FEV1/FVC&lt;70%, and FEV1&lt;30%, or (DLCO%) &lt; 40%.&#xD;
&#xD;
          -  12.Patients with acute onset or ongoing, pulmonary symptoms and interstitial lung&#xD;
             disease that the researchers considered not suitable for trail.&#xD;
&#xD;
          -  13. Patients with other factors the researchers considered not suitable for the trail&#xD;
             (for example, patients those who not willing to follow the procedure, limitation or&#xD;
             requirements, who once experienced bone marrow allotransplantation, who have other&#xD;
             kinds of malignant tumor coexisted or who showed allergic to the active ingredients or&#xD;
             inactive adjuvant of the investigational drug, as well as drugs with similar chemical&#xD;
             structure or in the same class).&#xD;
&#xD;
          -  14. Confirmed mutation of EGFR 20 exon insertion at anytime after the first diagnosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>cancer hospital Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

